<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0F9A2797-1EE6-48E6-8C12-0CC0B426575C"><gtr:id>0F9A2797-1EE6-48E6-8C12-0CC0B426575C</gtr:id><gtr:name>University of Aveiro</gtr:name><gtr:address><gtr:line1>Campo Universitario</gtr:line1><gtr:line4>Aveiro</gtr:line4><gtr:line5>3800</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Portugal</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EB4EED18-4D2E-4BF5-B732-A731B1DC6C51"><gtr:id>EB4EED18-4D2E-4BF5-B732-A731B1DC6C51</gtr:id><gtr:name>MRC Protein Phosphorylation Unit</gtr:name><gtr:address><gtr:line1>Department of Biochemistry</gtr:line1><gtr:line2>The University of Dundee</gtr:line2><gtr:line3>MSI/WTB Complex</gtr:line3><gtr:postCode>DD1 5EH</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EB4EED18-4D2E-4BF5-B732-A731B1DC6C51"><gtr:id>EB4EED18-4D2E-4BF5-B732-A731B1DC6C51</gtr:id><gtr:name>MRC Protein Phosphorylation Unit</gtr:name><gtr:address><gtr:line1>Department of Biochemistry</gtr:line1><gtr:line2>The University of Dundee</gtr:line2><gtr:line3>MSI/WTB Complex</gtr:line3><gtr:postCode>DD1 5EH</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0F9A2797-1EE6-48E6-8C12-0CC0B426575C"><gtr:id>0F9A2797-1EE6-48E6-8C12-0CC0B426575C</gtr:id><gtr:name>University of Aveiro</gtr:name><gtr:address><gtr:line1>Campo Universitario</gtr:line1><gtr:line4>Aveiro</gtr:line4><gtr:line5>3800</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Portugal</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/34A3A2B9-9F8D-4704-9DDC-534A423EF333"><gtr:id>34A3A2B9-9F8D-4704-9DDC-534A423EF333</gtr:id><gtr:firstName>Tricia</gtr:firstName><gtr:surname>Cohen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U127015389"><gtr:id>5C044ECE-F8C0-49AF-B3F2-BA7BF0373FE6</gtr:id><gtr:title>The regulation of protein phosphatase 1 by targetting subunits and their role in signal transduction</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U127015389</gtr:grantReference><gtr:abstractText>Diabetes affects 150 million people worldwide and type 2 diabetes linked with obesity is the major disease epidemic of the developed world, placing a huge burden on healthcare systems. One of the causes of high blood glucose levels in diabetics is the inability of insulin to stimulate the uptake of glucose from the blood and its conversion into the glucose storage molecule, glycogen. A major route by which the hormone insulin stimulates the synthesis of glycogen is through the removal of phosphate from the enzyme that makes glycogen, called glycogen synthase (GS). In the liver, phosphate is removed from GS by an enzyme called protein phosphatase 1 (PP1), which is attached to glycogen molecules through a targeting protein termed GL. We have shown that the amount of GL produced by the liver is regulated by the concentration of insulin in the blood. The speed with which PP1 can switch on GS activity is controlled by another protein which, when attached to one end of GL, switches off PP1. The aims of the project are to establish exactly how PP1 is regulated by insulin and glucose through changes in the concentration of the protein that attaches to GL and to discover how insulin controls the amount of GL that is made. These studies should establish whether a drug that prevents the attachment of GL to the regulator protein will be capable of lowering the level of glucose in the blood and hence be useful for the treatment of type 2 diabetes.</gtr:abstractText><gtr:technicalSummary>Diabetes affects 150 million people worldwide and type 2 diabetes linked with obesity is a major disease epidemic of the developed world, placing a huge burden on healthcare systems. One of the causes of high blood glucose levels in diabetics is the inability of insulin to stimulate the uptake of glucose and its conversion into glycogen. A major route by which insulin stimulates glycogen synthesis is through the dephosphorylation and activation of glycogen synthase (GS). The sites on GS that are phosphorylated by glycogen synthase kinase 3 (GSK3) in response to insulin are dephosphorylated by glycogen-targeted forms of protein phosphatase 1 (PP1). In liver, the major glycogen targeting subunit of PP1 is GL. In earlier studies we showed that the carboxy-terminal region of GL binds a regulator (phosphorylase a), which may provide a mechanism for inhibiting glycogen synthesis when glycogenolysis is activated and vice versa. We also showed that the expression level of GL is greatly enhanced by insulin. The aims of the proposed research are to investigate whether the hepatic glycogen-targeted form of protein phosphatase 1, PP1-GL, is controlled by insulin and glucose in vivo through changes in the level of phosphorylase a, and to identify the signalling pathways that regulate the insulin-dependent expression of GL. We will address these questions by generating a mouse model that expresses a mutated GL unable to bind phosphorylase a, and by examination of the sequences in the promoter region of GL gene that are responsive to insulin. We recently showed that the expression of two other, but less abundant, forms of hepatic glycogen-targeted PP1 are regulated by insulin and will therefore extend the study to these enzymes, as well as a further novel form of glycogen-targeted PP1 that was recently identified from human genome sequences. The major form of glycogen-targeted PP1 in skeletal muscle is PP1-GM, which may be involved in the stimulation of glycogen synthase. We aim to elucidate the modifications of skeletal muscle PP1-GM that contribute to the regulation glycogen synthase, and hence to the regulation of glycogen synthesis by exercise and hormones.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1991-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>310908</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Assessment of a potential drug target</gtr:description><gtr:id>D756F771-B730-487A-9A05-5F2CAB5CE301</gtr:id><gtr:impact>17870073</gtr:impact><gtr:outcomeId>71F1FFFC976-1</gtr:outcomeId><gtr:partnerContribution>After a talk I gave at Pfizer (Groton, CT USA), Judith Treadway suggested that a particular phosphorylase inhibitor, developed by Pfizer, might also inhibit the interaction of active phosphorylase with the hepatic glycogen targeting subunit of protein phosphatase 1. I was investigating the latter interaction as a potential pharmaceutical target for the treatment of hyperglycaemia and had presented our initial data to Pfizer. She later provided the drug for me to test.</gtr:partnerContribution><gtr:piContribution>We showed that the hepatic PP1 glycogen targeting subunit interaction with active phosphorylase involved mainly two tyrosines and was sufficiently small to be targeted by a small molecule drug. We demonstrated that the Pfizer phosphorylase inhibitor, not only inhibited phosphorylase but also the interaction with the hepatic glycogen targeting subunit. The results indicated that latter protein-protein interaction could be targeted independently of phosphorylase. The data further indicated that the indole-2 carboxamide series of phosphorylase inhibitors also activated glycogen targeted protein phosphatase 1.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Aveiro</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:description>A novel protein phosphatase 1 complex that interacts with DNA</gtr:description><gtr:id>6135B70D-70CA-45A5-8D13-9109532E23EC</gtr:id><gtr:impact>17123353</gtr:impact><gtr:outcomeId>DB323C749B0-1</gtr:outcomeId><gtr:partnerContribution>Edgar da Cruz e Silva's group identified one of three alternatively spliced forms of a novel protein (termed SARP) that interacted with protein phosphatase 1 (PP1) and was highly abundant in testis and sperm. With the antibodies we raised, they showed that SARP was abundant in the nucleus and bound to DNA. Collaboration led to more rapid determination of the biochemistry and putative function of the protein phosphatase 1 complex.</gtr:partnerContribution><gtr:piContribution>My group independently identified two of three alternatively spliced forms of the novel protein, SARP, and showed that it interacted with PP1. We raised antibodies to SARP that enabled us to show that it was ubiquitously expressed in all tissues, with highest PP1 activities in testis and brain. We identified sequence motifs suggesting that it might function as a transcription factor. I wrote the first draft of the manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>200575</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Diabetes UK</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:id>08BBE219-7187-4FDC-BDF2-B5F8B1F1893C</gtr:id><gtr:outcomeId>dqkyomnCUdr0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>47132</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRCT Development Gap Funding</gtr:description><gtr:end>2008-09-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>F3939E16-12C9-49A7-9680-E99C59033B9D</gtr:id><gtr:outcomeId>F50D21D7E610</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>From the known data, my prediction was that inhibiting the PP1-GL-phosphorylase a interaction should increase hepatic glycogen synthesis and thus have the potential to decrease blood glucose levels. My research showed that this protein-protein interaction was sufficiently small to be targeted by a small molecule drug. The animal model engineered on the basis on these results showed that glucose tolerance was increased in vivo, indicating that inhibiting the PP1-GL-phosphorylase a interaction should decrease hyperglycaemia. Patent EP 1107986</gtr:description><gtr:grantRef>MC_U127015389</gtr:grantRef><gtr:id>E1F4525B-2DFD-47DB-8BE6-164D059BE5EF</gtr:id><gtr:impact>The PP1-GL-Phosphorylase a interaction is a potential target for decreasing blood glucose levels and Boehringer Ingelheim Pharma GmbH &amp;amp; Co.KG have developed an inhibitor of the GL- phosphorylase a interaction based on my data.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>316350423A7</gtr:outcomeId><gtr:patentId>WO200012549</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>PP1-GL-Phosphorylase a interaction</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The antidiabetic drug metformin is believed to exert its beneficial effect by increasing the phosphorylation and thus activation of AMPK. My research has shown that depletion of the magnesium/manganese-dependent protein serine/threonine phosphatase, Ppm1E in cell cultures increases the phosphorylation of AMPK and that Ppm1E interacts with AMPK. The results indicate that Ppm1E is a potential anti-diabetic target. In addition, the observed synergystic increase in phosphorylation of AMPK by depletion of Ppm1E and treatment of cells with phenformin, an analogue of metformin, suggests that a combination of Ppm1E inhibition with low levels of metformin may be useful for eliminating the adverse effects of high doses of metformin.</gtr:description><gtr:grantRef>MC_U127015389</gtr:grantRef><gtr:id>311194D8-6A39-464A-9878-B8FFA71BFE89</gtr:id><gtr:impact>Ppm1E, is a potential anti-diabetic target.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>9EFF8A4E792</gtr:outcomeId><gtr:patentId>WO2008065397</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>AMPK phosphatases</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Antibodies have been raised to protein phosphatase 1 (PP1) isoforms, glycogen targeting subunits, PP1 interacting subunits, Mn-dependent protein phosphatases and phosphosporylation sites within these proteins.</gtr:description><gtr:id>CC2A32F7-D161-4BCE-9B98-3DDEC5BF7B61</gtr:id><gtr:impact>The antibodies provided the first identification of novel proteins and detection of others for which commercial antibodies are not available, as described in the publications and patent listed in other sections.</gtr:impact><gtr:outcomeId>8ACE81D6977</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Antibodies</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>cDNAs encoding glycogen targeting subunits, PP1 interacting subunits, Mn-dependent protein phosphatases, mutants or fragments thereof in a variety of plasmid vectors.</gtr:description><gtr:id>3FF9CCCC-9CBE-42E1-9FDA-BF22ABD993AD</gtr:id><gtr:impact>The cDNAs have enabled the physiological functions of the encoded proteins to be investigated/determined.</gtr:impact><gtr:outcomeId>2E1096E528A</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>cDNAs</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>GL-Y284F is a mouse line in which the hepatic glycogen targeting subunit of protein phosphatase 1 is modified; the carboxyterminal tyrosine is replaced by phenylalanine.</gtr:description><gtr:id>0A5155BD-B861-4CD2-9A37-B754D6CC1AE4</gtr:id><gtr:impact>The GL-Y284F mouse line shows improved glucose tolerance in both heterozygotes and homozygotes without causing significant accumulation of glycogen in liver or muscle as described in publication 19275933. This contrasts with phosphorylase inhibitors, which cause significant hyper-accumulation of glycogen and lose the initial improvement of glucose tolerance after a few months. The interaction of GL with active phosphorylase could therefore be a useful target for the treatment of hyperglycaemia.</gtr:impact><gtr:outcomeId>5FF6A1D5391</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GL-Y284F</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A95FBD3F-2A22-4864-966F-C2782FE10FD5</gtr:id><gtr:title>R3F, a novel membrane-associated glycogen targeting subunit of protein phosphatase 1 regulates glycogen synthase in astrocytoma cells in response to glucose and extracellular signals.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d69a23301ebf72701cede7f78faf5d5"><gtr:id>3d69a23301ebf72701cede7f78faf5d5</gtr:id><gtr:otherNames>Kelsall IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn><gtr:outcomeId>bAvbboZBkVc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77B836CC-0A03-4BA1-8C9A-181CBCAD7368</gtr:id><gtr:title>Disruption of the allosteric phosphorylase a regulation of the hepatic glycogen-targeted protein phosphatase 1 improves glucose tolerance in vivo.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d69a23301ebf72701cede7f78faf5d5"><gtr:id>3d69a23301ebf72701cede7f78faf5d5</gtr:id><gtr:otherNames>Kelsall IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>588A70837E0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C413001-D69A-412E-B9BA-805474D1C845</gtr:id><gtr:title>Disruption of the striated muscle glycogen-targeting subunit of protein phosphatase 1: influence of the genetic background.</gtr:title><gtr:parentPublicationTitle>Journal of molecular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72e155a53aa7fef54c165af079b2c954"><gtr:id>72e155a53aa7fef54c165af079b2c954</gtr:id><gtr:otherNames>Paterson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0952-5041</gtr:issn><gtr:outcomeId>FB21280C6E7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80BD7070-D435-4EFB-B985-E3AC4046A3B7</gtr:id><gtr:title>The hepatic PP1 glycogen-targeting subunit interaction with phosphorylase a can be blocked by C-terminal tyrosine deletion or an indole drug.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d69a23301ebf72701cede7f78faf5d5"><gtr:id>3d69a23301ebf72701cede7f78faf5d5</gtr:id><gtr:otherNames>Kelsall IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>C82927D4D9F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AF010E4-8E97-4F76-AC8E-F9D8F6A500E6</gtr:id><gtr:title>Glucose-6-phosphate-mediated activation of liver glycogen synthase plays a key role in hepatic glycogen synthesis.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44552267cb3ef7f933e1f80d112a76de"><gtr:id>44552267cb3ef7f933e1f80d112a76de</gtr:id><gtr:otherNames>von Wilamowitz-Moellendorff A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>sMjvGL3U4Xu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0695E29-48EA-4591-AEE5-F65D276030A5</gtr:id><gtr:title>SARP, a new alternatively spliced protein phosphatase 1 and DNA interacting protein.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c9b51c9b3b5a3d1ba7b2c07f59e5af2"><gtr:id>2c9b51c9b3b5a3d1ba7b2c07f59e5af2</gtr:id><gtr:otherNames>Browne GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>F4FA1EF8903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CB6976C-ACD4-4C92-893C-AC58459D8C10</gtr:id><gtr:title>Ppm1E is an in cellulo AMP-activated protein kinase phosphatase.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da1df71f13ee89fd3fc5bb0ab619ebe0"><gtr:id>da1df71f13ee89fd3fc5bb0ab619ebe0</gtr:id><gtr:otherNames>Voss M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>d2FDMA3XQu7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AC60989-85E2-4384-A827-4D7DC3F0A777</gtr:id><gtr:title>Protein domains in the hepatic glycogen-targetting subunit of protein phosphatase 1 and methods of making and using the same</gtr:title><gtr:parentPublicationTitle>European Patent</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1feb85e98391ea9e809755cae8c877d9"><gtr:id>1feb85e98391ea9e809755cae8c877d9</gtr:id><gtr:otherNames>Cohen, P.T.W.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>43BA41A8DF1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C02449D8-C708-4489-9640-7072F00DBF23</gtr:id><gtr:title>The skeletal muscle-specific glycogen-targeted protein phosphatase 1 plays a major role in the regulation of glycogen metabolism by adrenaline in vivo.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6670f59e924bc6b23cef077d6e7b2c8e"><gtr:id>6670f59e924bc6b23cef077d6e7b2c8e</gtr:id><gtr:otherNames>Toole BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>384D51AC92A</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U127015389</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>